SCHEMBL7535534

SCHEMBL7535534

COc1ccc(S(=O)(=O)c2c(F)c(F)c(NS(=O)(=O)C(F)(F)F)c(F)c2F)cc1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 2/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
MAPK1 P28482 2/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 2/20 0.38
HCRTR1 O43613 1/20 0.38
POLB P06746 1/20 0.38
PTGS1 P23219 2/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
CA2 P00918 3/20 0.37
CA1 P00915 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
LMNA P02545 5/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 3/20 0.36
PDE4D Q08499 1/20 0.36
HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537217 0.88 KMT2A (0.44) TUBB1MEN1KMT2AMAPK1ALOX15
SCHEMBL7534198 0.87 TUBB1 (0.42) TUBB1MEN1KMT2AMAPK1TSHR
SCHEMBL7536278 0.84 MEN1 (0.51) MEN1KMT2AHCRTR1POLBL3MBTL1
SCHEMBL7535465 0.84 TUBB1 (0.50) TUBB1MAPK1TSHRPOLBPTGS1
SCHEMBL7540113 0.83 L3MBTL1 (0.42) MEN1KMT2AMAPK1ALOX15TSHR
SCHEMBL7534084 0.80 PKM (0.47) MEN1KMT2APTGS1CA2CA1
SCHEMBL7533957 0.79 TUBB1 (0.46) TUBB1MEN1KMT2AMAPK1TSHR
SCHEMBL7534356 0.79 TUBB1 (0.46) TUBB1MEN1KMT2AMAPK1TSHR
SCHEMBL7534000 0.78 TUBB1 (0.40) TUBB1MEN1KMT2AMAPK1ALOX15
SCHEMBL7534009 0.77 TUBB1 (0.44) TUBB1MEN1KMT2AMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 TUBB1 446/4885MEN1 2231/4885KMT2A 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.